Q-omics provides the consensus-scored KRTDAP profile across patient tissues and cancer cell-line models. KRTDAP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KRTDAP is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, KRTDAP RNA expression shows 13,963 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LUSC, and TGCT as cancer lineages where KRTDAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTDAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTDAP survival associations across molecular data types. KRTDAP RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTDAP RNA expression–survival associations across cancer types. High KRTDAP expression shows unfavorable associations in ACC, BLCA, SKCM, PRAD, COAD and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KRTDAP RNA expression.
This table summarizes KRTDAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KRTDAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTDAP shows lower tumor expression in KICH, LUAD and THCA and higher tumor expression in LUSC, BLCA and CHOL. The LUSC box plot shows higher KRTDAP RNA expression in tumor versus normal tissue (log2 FC = +3.330, t-test p < 0.001).
This table shows molecular features associated with KRTDAP in patient tissues and cancer cell lines. In patient samples, KRTDAP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTDAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
